Bates ML, Farrell ET, Eldridge MW Abnormal ventilatory responses in adults born prematurely. N Engl J Med. 2014 Feb 6;370(6):584-5. doi: 10.1056/NEJMc1311092.
Bates ML, Pillers DA, Palta M, Farrell ET, Eldridge MW Ventilatory control in infants, children, and adults with bronchopulmonary dysplasia. Respir Physiol Neurobiol. 2013 Nov 1;189(2):329-37. doi: 10.1016/j.resp.2013.07.015. Epub 2013 Jul 22. Review.
Evans M, Palta M, Sadek M, Weinstein MR, Peters ME Associations between family history of asthma, bronchopulmonary dysplasia, and childhood asthma in very low birth weight children. Am J Epidemiol. 1998 Sep 1;148(5):460-6.
Hagen EW, Sadek-Badawi M, Carlton DP, Palta M Permissive hypercapnia and risk for brain injury and developmental impairment. Pediatrics. 2008 Sep;122(3):e583-9. doi: 10.1542/peds.2008-1016.
Hagen EW, Sadek-Badawi M, Palta M Daycare attendance and risk for respiratory morbidity among young very low birth weight children. Pediatr Pulmonol. 2009 Nov;44(11):1093-9. doi: 10.1002/ppul.21104.
McManus BM, Robert S, Albanese A, Sadek-Badawi M, Palta M Predictors of receiving therapy among very low birth weight 2-year olds eligible for Part C early intervention in Wisconsin. BMC Pediatr. 2013 Jul 11;13:106. doi: 10.1186/1471-2431-13-106.
McManus BM, Robert S, Albanese A, Sadek-Badawi M, Palta M Racial disparities in health-related quality of life in a cohort of very-low-birth-weight 2- and 3-year-olds with and without asthma. J Epidemiol Community Health. 2012 Jul;66(7):579-85. doi: 10.1
McManus BM, Robert SA, Albanese A, Sadek-Badawi M, Palta M Racial disparities in health-related quality of life in a cohort of very low birthweight 2- and 3-year-olds with and without cerebral palsy. Dev Med Child Neurol. 2011 May;53(5):467-9. doi: 10.11
McManus BM, Robert SA, Albanese A, Sadek-Badawi M, Palta M Relationship between neighborhood disadvantage and social function of Wisconsin 2- and 3-year-olds born at very low birth weight. Arch Pediatr Adolesc Med. 2011 Feb;165(2):119-25. doi: 10.1001/ar
Palta M, Gabbert D, Weinstein MR, Peters ME Multivariate assessment of traditional risk factors for chronic lung disease in very low birth weight neonates. The Newborn Lung Project. J Pediatr. 1991 Aug;119(2):285-92.
Palta M, Sadek M, Lim TS, Evans M, McGuinness G Association of tocolytic therapy with antenatal steroid administration and infant outcomes. Newborn Lung Project. Am J Perinatol. 1998 Feb;15(2):87-92.
Palta M, Sadek-Badawi M, Carlton DP Association of BPD and IVH with early neutrophil and white counts in VLBW neonates with gestational age <32 weeks. J Perinatol. 2008 Sep;28(9):604-10. doi: 10.1038/jp.2008.65. Epub 2008 Jun 19.
Palta M, Sadek-Badawi M, Madden K, Green C Pulmonary testing using peak flow meters of very low birth weight children born in the perisurfactant era and school controls at age 10 years. Pediatr Pulmonol. 2007 Sep;42(9):819-28.
Palta M, Sadek-Badawi M PedsQL relates to function and behavior in very low and normal birth weight 2- and 3-year-olds from a regional cohort. Qual Life Res. 2008 Jun;17(5):691-700. doi: 10.1007/s11136-008-9346-1. Epub 2008 May 6.
Weinstein MR, Peters ME, Sadek M, Palta M A new radiographic scoring system for bronchopulmonary dysplasia. Newborn Lung Project. Pediatr Pulmonol. 1994 Nov;18(5):284-9.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
